Characterization of molecular subtypes of Korean breast cancer: An ethnically and clinically distinct population

International Journal of Oncology

Volumn 37, Issue 1, 2010, Pages 51-59

  Han, Wonshik ^a   Nicolau, Monica ^b   Noh, Dong Young ^a   Jeffrey, Stefanie S ^c  

^a Seoul National University College of Medicine   (South Korea)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asian; Breast neoplasms; Gene expression profiling; Prognosis; Race

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HORMONE RECEPTOR; KI 67 ANTIGEN; METHOTREXATE; PROTEIN P53; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DISEASE FREE SURVIVAL; ETHNICITY; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; KOREA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST TUMOR; CARCINOMA; CLASSIFICATION; CLUSTER ANALYSIS; DNA MICROARRAY; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MOLECULAR DIAGNOSIS; POPULATION GENETICS; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CARCINOMA; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS, POPULATION; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; YOUNG ADULT;

EID: 77953193699     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000652     Document Type: Article

References (30)

1. Wiencke JK: Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer 4: 79-84, 2004. (Pubitemid 38082156)
2. Ahn SH: Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg 139: 27-31, 2004.
3. Yoo KY, Kang D, Park SK, et al: Epidemiology of breast cancer in Korea: occurrence, high-risk groups, and prevention. J Korean Med Sci 17: 1-6, 2002.
4. Han W, Kim SW, Park IA, et al: Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4: 82, 2004.
5. Ahn SH, Son BH, Kim SW, et al: Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea - a report from the korean breast cancer society. J Clin Oncol 25: 2360-2368, 2007.
6. Choi DH, Shin DB, Lee MH, et al: A comparison of five immunohistochemical biomarkers and her-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 98: 1587-1595, 2003.
7. Choi DH, Lee MH, Bale AE, Carter D and Haffty BG: Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22: 1638-1645, 2004. (Pubitemid 41079802)
8. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
9. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
10. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
11. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003.
12. Jung SY, Han W, Lee JW, et al: Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 16: 1112-1121, 2009.
13. Zhao H, Hastie T, Whitfield ML, Borresen-Dale AL and Jeffrey SS: Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics 3: 31, 2002.
14. Gollub J, Ball CA, Binkley G, et al: The Stanford Microarray Database: data access and quality assessment tools. Nucleic Acids Res 31: 94-96, 2003.
15. Sherlock G, Hernandez-Boussard T, Kasarskis A, et al: The Stanford Microarray Database. Nucleic Acids Res 29: 152-155, 2001.
16. Tibshirani R, Hastie T, Narasimhan B and Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99: 6567-6572, 2002.
17. Troyanskaya O, Cantor M, Sherlock G, et al: Missing value estimation methods for DNA microarrays. Bioinformatics 17: 520-525, 2001.
18. Sagara Y, Mimori K, Yoshinaga K, et al: Clinical significance of caveolin-1, caveolin-2 and her2/neu mRNA expression in human breast cancer. Br J Cancer 91: 959-965, 2004.
19. Sloan EK, Stanley KL and Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23: 7893-7897, 2004.
20. Williams TM, Cheung MW, Park DS, et al: Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 14: 1027-1042, 2003.
21. Finlin BS, Gau CL, Murphy GA, et al: Rerg is a novel rasrelated, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem 276: 42259-42267, 2001.
22. Perou CM, Jeffrey SS, van de Rijn M, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212-9217, 1999.
23. Gruvberger S, Ringner M, Chen Y, et al: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61: 5979-5984, 2001.
24. Van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
25. West M, Blanchette C, Dressman H, et al: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98: 11462-11467, 2001.
26. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102: 3738-3743, 2005.
27. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
28. Van de Rijn M, Perou CM, Tibshirani R, et al: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991-1996, 2002.
29. Kun Y, How LC, Hoon TP, et al: Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genet 12: 3245-3258, 2003.
30. Dontu G, El-Ashry D and Wicha MS: Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15: 193-197, 2004. (Pubitemid 38833988)